KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Interest Expenses (2018 - 2025)

TherapeuticsMD filings provide 12 years of Interest Expenses readings, the most recent being $3000.0 for Q3 2025.

  • On a quarterly basis, Interest Expenses changed 0.0% to $3000.0 in Q3 2025 year-over-year; TTM through Mar 2026 was $5000.0, a 50.0% decrease, with the full-year FY2021 number at $22.6 million, down 13.36% from a year prior.
  • Interest Expenses hit $3000.0 in Q3 2025 for TherapeuticsMD, up from $2000.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $14.4 million in Q1 2022 to a low of $2000.0 in Q1 2025.
  • Median Interest Expenses over the past 5 years was $45000.0 (2023), compared with a mean of $3.3 million.
  • Biggest five-year swings in Interest Expenses: skyrocketed 63.32% in 2021 and later crashed 99.65% in 2023.
  • TherapeuticsMD's Interest Expenses stood at $5.4 million in 2021, then soared by 167.24% to $14.4 million in 2022, then crashed by 99.86% to $20000.0 in 2023, then crashed by 85.0% to $3000.0 in 2024, then changed by 0.0% to $3000.0 in 2025.
  • The last three reported values for Interest Expenses were $3000.0 (Q3 2025), $2000.0 (Q2 2025), and $2000.0 (Q1 2025) per Business Quant data.